In particular, the study of lymphoma in dogs offers insight into the efficacy of inhibitors targeting key pathways like NF-κB and PI3K/Akt/mTOR and how immunotherapies such as monoclonal antibodies and CAR-T cell treatments can be adapted for veterinary use. Here, NFKB1 is linked to lymphoma.